MesaGreen K9MGP Seizure Program
August 2019
In July 2019, MesaGreen Pharmaceutical (MGP) entered into a research agreement with the University of Minnesota Schools of Veterinary Medicine and Pharmacy and the Mayo Clinic to evaluate the ability of compound K9MGP to produce a cessation of ongoing seizures in canines. The study consisted of evaluating the drug given both intravenously (IV) and intramuscularly (IM) in two dogs with either a history of seizures or who were currently on medication to present seizures. One of the animals had implanted electrodes in the skull, which allowed for monitoring brain wave activity, referred to as an electroencephalogram (EEG).